Surmodics Issues FY19 Outlook – Quick Facts

Surmodics, Inc. (SRDX) announced, for fiscal year 2019, the company expects non-GAAP result per share to be between a loss of $0.07 and profit of $0.23 per share. Revenue is expected to to range from $92 million to $97 million.

On a non-GAAP basis, earnings per share were $0.05 in the fourth quarter, as compared with $0.18 in the year-ago period. Total revenue was $23.0 million, as compared with $20.1 million in the prior-year period. Medical Device revenue was $17.0 million in the fourth quarter, compared with $14.7 million in the year-ago period, an increase of 15.4%, and included $2.2 million from SurVeil agreement with Abbott.

Source: Read Full Article